SavedAdd your journal

Journals / Turkish Thoracic Journal / 2021 / Cilt: 22 - Sayı: 6

COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome

Sadi Can SÖNMEZ
Zeynep Büşra KISAKÜREK
Ayşe Bilge ÖZTÜRK
Süda TEKIN
Pages
501–506
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

SÖNMEZ, S. C., KISAKÜREK, Z. B., ÖZTÜRK, A. B., TEKIN, S. (2021). COVID-19, Severe Asthma and Omalizumab Therapy: A Case-Based Inquiry into Associations, Management, and the Possibility of a Better Outcome. Turkish Thoracic Journal, Cilt: 22 - Sayı: 6, 501–506. https://ajindex.com/articles/417921

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021
  2. 76(2):428-455. [CrossRef] 2. Öztürk AB, Bavbek S. Role of SARS-CoV-2 in asthma exacerbations. Asthma Allergy Immunol. 2020
  3. [CrossRef] 3. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020
  4. 75(7):1730-1741. [CrossRef] 4. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020
  5. 146(1):110-118. [CrossRef] 5. Hartmann-Boyce J, Gunnell J, Drake J, et al. Asthma and COVID-19: review of evidence on risks and management considerations. BMJ Evid Based Med. 2020:bmjebm-2020-111506. [CrossRef] 6. Ozturk AB, Baççıoğlu A, Soyer O, et al. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol. 2021
  6. 182(1): 49-52. [CrossRef] 7. Vultaggio A, Agache I, Akdis CA, et al. Considerations on BioLogicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy. 2020
  7. 75(11):2764-2774. [CrossRef] 8. Turkish Ministry of Health. Covid-19 (Sars-Cov-2 infection) Guide: Study of Scientific Board. Available at: https://hs gm.sa glik. gov.t r/dep o/bir imler /goc_ sagli gi/co vid19 /rehb er/CO VID-1 9_Reh beri2 02004 14_en g_v4_ 002_1 4.05. 2020. pdf. Accessed March 3, 2021. 9. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention.Updated 2020. Available at: https://gi nasth ma.or g/wp- conte nt/up loads /2020 /04/G INA-2 020-f ull-r eport -fin al-_w ms.pd f. Accessed March 4, 2021. 10. Öztürk AB, Çağlayan B. Angiotensin converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk. Eur Ann Allergy Clin Immunol. 2020
  8. 52(6):282-285. [CrossRef] 11. Roncati L, Nasillo V, Lusenti B, Riva G. Signals of Th2 immune response from COVID-19 patients requiring intensive care. Ann Hematol. 2020
  9. 99(6):1419-1420. [CrossRef] 12. Edwards MR, Strong K, Cameron A, et al. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017
  10. 140(4):909-920. [CrossRef] 13. Hussein MH, Elshazli RM, Attia AS, et al. Asthma and COVID- 19
  11. different entities, same outcome: a meta-analysis of 107,983 patients. J Asthma. 2021:1-8. [CrossRef] 14. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients